Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Every two years, the WHO Model Essential Medicines List is revised by a committee comprised of experts from the
research, medical, academic and pharmaceutical fields.
The Model EML offer guidance on which medicines should be prioritized based on a public health and clinical
perspectives, based on their efficacy, safety and cost-effectiveness. This years revision and addition of large
number of new drugs, even when new drugs are expensive, highlighted the importance of promoting equal access
to essential medicines.
When countries revise their own national EML based on the WHO Model EML this opens up the opportunity to
increase access to these new medicines through financing via government and donor resources. In case of hepatitis,
MDR-TB and cancer significant number of new medicines were added to Model EML
for treatment hepatitis B, entecavir and tenofovir for the treatment of hepatitis B, and fir hepatitis C:
and the addition of six oral direct-acting antiviral medicines including daclatasvir, ledipasvir +
sofosbuvir, ombitasvir + paritaprevir + ritonavir with or without dasabuvir, simeprevir, and
sofosbuvir,
See also WHO press release and executive summary and fact sheets at the end
The meeting of the 20th Expert Committee on the Selection and Use of Essential Medicines was held from 20 to 24
April 2015 at WHO Headquarters. The Expert Committee considered 77 applications for medicines to be added to
the 18th WHO Model List of Essential Medicines (EML) and the 4th WHO Model List of Essential Medicines for
Children (EMLc). WHO technical departments were involved and consulted with regard to applications relating to
their disease areas.
Related links
Essential Medicines List 2015
Essential Medicines List Children 2015
Executive summary
Hepatitis C WHO fact sheet
Cancer WHO fact sheet
TB WHO fact sheet
Media contact
Daniela Bagozzi, WHO
Telephone: +41 79 6037281
E-mail: bagozzid@who.int